The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...

The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), ...

Discover how kidney function decline in ATTR-CM patients predicts higher mortality, highlighting its role as a critical marker in disease management and care optimisation.

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

A new type of therapy that 'edits' a gene in patients with a rare heart condition has been shown to be safe and effective, according to research from UCL and the Royal Free Hospital. Results for the ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software that helps with the early diagnosis of cardiac amyloidosis, enabling timely ...

ccf.org Given increased awareness and improved non-invasive diagnostic tools, cardiac amyloidosis has become an increasingly recognised aetiology of increased ventricular wall thickness and heart ...

Individuals with pre-existing heart problems may be more at risk from the negative consequences of air pollution on heart health, a study by Intermountain Health, Salt Lake City, has found.

Kavita Sharma, Director of Heart Failure and Cardiac Transplantation, presents a patient case on amyloidosis. She provides an explanation of amyloidosis along with new treatment and therapy options ...

Weight-Loss Drug Reduces Risk of Early Death for Patients With Heart Failure, Trial Finds Nov. 20, 2024 — Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening ...